RT Book, Section
A1 Morgensztern, Daniel
A1 Herbst, Roy S.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105848056
T1 Genomics, Molecular Markers, and Targeted Therapies in Non Small-Cell Lung Cancer
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105848056
RD 2024/04/23
AB Lung  cancer  is  the  most  frequent  invasive  malignancy  and  the  common  cause  of  cancer  death  worldwide  with  an  estimated  1.60  million  new  cases  and  1.37  million  deaths  in  2008.1  Non  small-cell  lung  cancer  (NSCLC),  the  broad  category  that  accounts  for  approximately  87%  of  all  patients  with  lung  cancer,  usually  presents  at  an  advanced  stage,  where  the  treatment  is  essentially  palliative.  The  survival  improvement  for  unselected  patients  with  metastatic  NSCLC  has  been  modest,  with  a  large  surveillance,  epidemiology,  and  end  results  (SEER)  study,  from  the  periods  1990–1993  to  2002–2005,  showing  increased  survivals  at  1  and  2  years  of  13.2%  to  19.4%  and  4.5%  to  7.8%,  respectively.2  More  recently,  however,  there  has  been  a  significant  improvement  in  the  understanding  of  the  biology  of  lung  cancer,  with  the  discovery  of  new  targets  and  development  of  several  drugs  with  novel  mechanisms  of  action.  This  chapter  reviews  the  current  knowledge  of  cancer  genomics,  the  use  of  molecular  markers,  and  results  from  clinical  trials  that  are  changing  the  therapeutic  landscape  of  NSCLC.